World's Best Scientists 2026 revealed!
Franz X. Vollenweider

Franz X. Vollenweider

Award Badge
Psychology
Switzerland
2026

D-Index & Metrics

Psychology

D-Index
84
Citations
25072
World Ranking
1232
National Ranking
13

Franz X. Vollenweider publication distribution in Psychology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Psychology in 2026. The highlighted bar marks where Franz X. Vollenweider sits on this spectrum.

31–40 publications: 6 scientists 41–50 publications: 52 scientists 51–60 publications: 138 scientists 61–70 publications: 299 scientists 71–80 publications: 461 scientists 81–90 publications: 605 scientists 91–100 publications: 713 scientists 101–110 publications: 736 scientists 111–120 publications: 686 scientists 121–130 publications: 670 scientists 131–140 publications: 644 scientists 141–150 publications: 597 scientists 151–160 publications: 576 scientists 161–170 publications: 477 scientists 171–180 publications: 450 scientists 181–190 publications: 397 scientists 191–200 publications: 343 scientists 201–210 publications: 328 scientists 211–220 publications: 313 scientists 221–230 publications: 283 scientists 231–240 publications: 226 scientists 241–250 publications: 196 scientists 251–260 publications: 201 scientists 261–270 publications: 171 scientists 271–280 publications: 151 scientists 281–290 publications: 139 scientists 291–300 publications: 113 scientists 301–310 publications: 102 scientists 311–320 publications: 100 scientists 321–330 publications: 76 scientists 331–340 publications: 92 scientists 341–350 publications: 85 scientists 351–360 publications: 69 scientists 361–370 publications: 71 scientists 371–380 publications: 63 scientists 381–390 publications: 58 scientists 391–400 publications: 57 scientists 401–410 publications: 43 scientists 411–420 publications: 33 scientists 421–430 publications: 50 scientists 431–440 publications: 41 scientists 441–450 publications: 32 scientists 451–460 publications: 27 scientists 461–470 publications: 28 scientists 471–480 publications: 25 scientists 481–490 publications: 28 scientists 491–500 publications: 20 scientists 501–510 publications: 23 scientists 511–520 publications: 26 scientists 521–530 publications: 17 scientists 531–540 publications: 21 scientists 541–550 publications: 14 scientists 551–560 publications: 16 scientists 561–570 publications: 10 scientists 571–580 publications: 22 scientists 581–590 publications: 9 scientists 591–600 publications: 14 scientists 601–610 publications: 9 scientists 611–620 publications: 11 scientists 621–630 publications: 4 scientists 631–640 publications: 7 scientists 641–650 publications: 5 scientists 651–660 publications: 10 scientists 661–670 publications: 8 scientists 671–680 publications: 8 scientists 681–690 publications: 4 scientists 691–700 publications: 3 scientists 701–704 publications: 4 scientists 705+ publications: 100 scientists
31 publications 705+

This scientist: 223 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 705 publications or more.

Franz X. Vollenweider D-index placement in Psychology in 2026

The chart shows the D-index (discipline H-index) distribution of Psychology scientists ranked by Research.com in 2026. The highlighted bar marks where Franz X. Vollenweider sits on this spectrum.

30–31 D-Index: 398 scientists 32–33 D-Index: 702 scientists 34–35 D-Index: 671 scientists 36–37 D-Index: 659 scientists 38–39 D-Index: 641 scientists 40–41 D-Index: 671 scientists 42–43 D-Index: 617 scientists 44–45 D-Index: 558 scientists 46–47 D-Index: 495 scientists 48–49 D-Index: 487 scientists 50–51 D-Index: 445 scientists 52–53 D-Index: 390 scientists 54–55 D-Index: 408 scientists 56–57 D-Index: 345 scientists 58–59 D-Index: 325 scientists 60–61 D-Index: 321 scientists 62–63 D-Index: 248 scientists 64–65 D-Index: 290 scientists 66–67 D-Index: 218 scientists 68–69 D-Index: 219 scientists 70–71 D-Index: 215 scientists 72–73 D-Index: 183 scientists 74–75 D-Index: 169 scientists 76–77 D-Index: 132 scientists 78–79 D-Index: 137 scientists 80–81 D-Index: 120 scientists 82–83 D-Index: 112 scientists 84–85 D-Index: 86 scientists 86–87 D-Index: 101 scientists 88–89 D-Index: 83 scientists 90–91 D-Index: 77 scientists 92–93 D-Index: 70 scientists 94–95 D-Index: 78 scientists 96–97 D-Index: 58 scientists 98–99 D-Index: 53 scientists 100–101 D-Index: 57 scientists 102–103 D-Index: 48 scientists 104–105 D-Index: 53 scientists 106–107 D-Index: 46 scientists 108–109 D-Index: 24 scientists 110–111 D-Index: 35 scientists 112–113 D-Index: 27 scientists 114–115 D-Index: 32 scientists 116–117 D-Index: 31 scientists 118–119 D-Index: 22 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 24 scientists 124–125 D-Index: 18 scientists 126–127 D-Index: 11 scientists 128–129 D-Index: 19 scientists 130–131 D-Index: 10 scientists 132–133 D-Index: 16 scientists 134–135 D-Index: 10 scientists 136–137 D-Index: 12 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 5 scientists 142–143 D-Index: 12 scientists 144+ D-Index: 98 scientists
30 D-Index 144+

This scientist: 84 D-Index — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 144 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Psychology in Switzerland Leader Award
  • 2025 - Research.com Psychology in Switzerland Leader Award

Overview

Franz X. Vollenweider is affiliated with the University of Zurich in Switzerland. Their research primarily focuses on the intersections of psychology and neuroscience, particularly exploring the mechanisms and effects of psychedelic substances within psychiatric contexts.

Their recent publications include:

  • Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders, 2020, Nature reviews. Neuroscience
  • Classic Psychedelic Drugs: Update on Biological Mechanisms, 2022, Pharmacopsychiatry

Vollenweider has contributed to fields encompassing Psychology and Neuroscience, with a strong emphasis on Clinical Psychology and Cellular and Molecular Neuroscience. Their work spans several subfields such as Cognitive Neuroscience, Organic Chemistry, and Experimental and Cognitive Psychology.

The main topics of their research can be summarized as:

  • Psychedelics and Drug Studies
  • Neurotransmitter Receptor Influence on Behavior
  • Chemical synthesis and alkaloids
  • Mental Health Research Topics
  • Functional Brain Connectivity Studies
  • Neural dynamics and brain function
  • Tryptophan and brain disorders

Frequent coauthors include:

  • Katrin H. Preller (43 joint publications)
  • Nathalie M. Rieser (16 joint publications)
  • Alan Anticevic (16 joint publications)
  • Flora Moujaes (15 joint publications)
  • Erich Seifritz (13 joint publications)

Research output by Vollenweider has been published in venues such as bioRxiv (Cold Spring Harbor Laboratory), Biological Psychiatry, eLife, Scientific Reports, and Neuroscience Applied. These publication venues highlight an engagement with a broad spectrum of scientific discussions, from preprint platforms to peer-reviewed journals in neuroscience and psychiatry.

Best Publications

  • Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.

    Franz X. Vollenweider;Margreet F. I. Vollenweider-Scherpenhuyzen;Andreas Bäbler;Helen Vogel

  • The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

    Franz X. Vollenweider;Michael Kometer

  • Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV)

    Erich Studerus;Alex Gamma;Franz X. Vollenweider

  • Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers: Implications for Models of Cognitive Deficits in Schizophrenia

    Daniel Umbricht;Liselotte Schmid;Rene Koller;Franz X. Vollenweider

  • Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.

    Erich Studerus;Michael Kometer;Felix Hasler;Franz X Vollenweider

  • Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers

    Franz X. Vollenweider;Alex Gamma;Matthias Liechti;Theo Huber

  • Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis

    FX Vollenweider;Klaus Leenders;C Scharfetter;P Maguire

  • Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose?effect study

    Felix Hasler;Ulrike Grimberg;Marco A. Benz;Theo Huber

  • Serotonin research: contributions to understanding psychoses.

    Mark A. Geyer;Franz X. Vollenweider

  • Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders.

    Franz X Vollenweider;Katrin H Preller

  • Gender differences in the subjective effects of MDMA.

    Matthias E. Liechti;Alex Gamma;Franz X. Vollenweider

  • Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects

    Yasmin Schmid;Florian Enzler;Peter Gasser;Eric Grouzmann

  • Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

    F.X. Vollenweider;K.L. Leenders;I. Øye;D. Hell

  • A systems model of altered consciousness: integrating natural and drug-induced psychoses.

    Franz X Vollenweider;Mark A Geyer

  • The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation

    Katrin H. Preller;Marcus Herdener;Thomas Pokorny;Amanda Planzer

  • Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

    F.X Vollenweider;K.L Leenders;C Scharfetter;A Antonini

  • Prediction of Psilocybin Response in Healthy Volunteers

    Erich Studerus;Alex Gamma;Michael Kometer;Franz X. Vollenweider

  • Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.

    Katrin H Preller;Joshua B Burt;Jie Lisa Ji;Charles H Schleifer

  • Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations

    Michael Kometer;André Schmidt;Lutz Jäncke;Franz X. Vollenweider

  • Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

    Unknown

  • 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.

    Franz X Vollenweider;Peter Vontobel;Daniel Hell;Klaus L Leenders

  • Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram.

    Matthias E Liechti;Christine Baumann;Alex Gamma;Franz X Vollenweider

Frequent Co-Authors

Katrin H. Preller
Katrin H. Preller University of Zurich
Erich Seifritz
Erich Seifritz University of Zurich
Daniel Hell
Daniel Hell University of Zurich
Mark A. Geyer
Mark A. Geyer University of California, San Diego
Boris B. Quednow
Boris B. Quednow University of Zurich
André Schmidt
André Schmidt University of Basel
Klaas E. Stephan
Klaas E. Stephan University of Zurich
Klaus L. Leenders
Klaus L. Leenders University Medical Center Groningen
Alan Anticevic
Alan Anticevic Yale University
Joram Feldon
Joram Feldon ETH Zurich

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a psychology degree in the USA opens doors to a variety of online degrees and rewarding careers, particularly in the growing field of speech-language pathology. Students often explore specialized paths like speech therapy, which require a blend of psychological understanding and clinical practice.

Becoming a speech therapist usually involves earning a relevant graduate degree, completing supervised clinical hours, and obtaining state certification. For instance, those interested in working in Rhode Island should familiarize themselves with the Rhode Island slp certification requirements. Similarly, becoming a speech therapist in South Carolina involves its own specific licensure process.

Requirements can vary significantly between states. Understanding the South Dakota slp certification requirements or the steps to becoming a speech therapist in Tennessee is essential for anyone planning to practice there. Prospective students are encouraged to research each state’s standards as they explore related online programs and future career paths.

Best Scientists Citing Franz X. Vollenweider

Trending Scientists

Recently Published Articles